Sonal Choudhary

Dr. Sonal Choudhary

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2025 in Dermato
Verified
Journal Article
Open access
PDF file
ASAlana Sadur
Alana Sadur
LJLucie Joerg
Lucie Joerg
ADAmelia Grace Stapleton Van Doren
Amelia Grace Stapleton Van Doren
ELEllen Tse-Yi Lee
Ellen Tse-Yi Lee
DSDia Shah
Dia Shah
SCSonal Choudhary
Sonal Choudhary
Sleep is crucial to overall health and plays a significant role in skin function. While the circadian rhythm has been extensively researched for its impact on the body’s optimal functioning, the skin also possesses an independent circadian system that serves many important functions. Sleep disruptions or deprivation can significantly affect skin conditions, by compromising the skin barrier and impairing processes such as collagen production, cellular repair, and wound healing. Given the commonality of sleep disturbances, it is crucial to understand the connection between sleep, circadian regulation, and skin health. This is particularly important in understudied populations, such as those with occupational sleep disruption and individuals with hormone-related conditions like PCOS and menopause. Bidirectional relationships have been established between sleep and several inflammatory skin conditions, including atopic dermatitis, psoriasis, rosacea, and hidradenitis suppurativa. While acne is influenced by sleep, the reverse relationship, how acne affects sleep quality, has not been well established. Chronic sleep disruption can increase cortisol levels and oxidative stress, both of which contribute to skin aging and the progression of autoimmune skin conditions, including systemic lupus erythematosus. As sleep is a modifiable risk factor, it is crucial to consider therapeutic options and interventions to prevent or alleviate skin conditions. This review discusses various therapeutic approaches, including melatonin, L-Theanine, Magnesium-L-threonate, Inositol, Cinnamomi cortex, nervous system regulation, and proper sleep hygiene. These therapeutic options have been studied for their impact on sleep, and importantly, several have been evaluated for their utility as adjuncts for treating skin conditions. Overall, the relationship between sleep and skin health is clear, and incorporating sleep-focused therapeutic interventions offers potential to improve both sleep quality and skin health in individuals with a variety of skin conditions.

1 September 2023 in Hematology Reports
Verified
Journal Article
Open access
PDF file
AXAmy Xiao
Amy Xiao
CBColleen J. Beatty
Colleen J. Beatty
SCSonal Choudhary
Sonal Choudhary
Oleg E AkilovOleg E Akilov
Oleg E Akilov
Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT), is a rare and aggressive variant of primary cutaneous lymphoma that typically expresses B cells as well as MUM1/IRF4, BCL2, and FOXP1, whereas BCL6 may be present or undetectable. We present a case of CD5+ PCDLBCL-LT presenting as a 6 mm pink-bluish nodule on the mid-left thigh, which was concerning for basal cell carcinoma. The histological examination reveals the presence of an intradermal proliferation of large, atypical CD5+, CD20+ BCL2+, BCL6+, MUM-1+, and Cyclin-D1+ lymphocytes in a nodular, diffuse interstitial and perivascular distribution. Because the patient presented with a small, single nodule, the systemic treatment of multiagent chemotherapy was avoided and localized electron beam radiation therapy with rituximab was initiated instead, achieving complete response. Early identification of PCDLBCL-LT is key for maximal therapeutic benefit and prognosis; it is important to consider PCDLBCL-LT on the differential when evaluating small, single nodules on the lower extremities of elderly patients.

3 July 2025 in Journal of the American Academy of Dermatology
Verified
Journal Article
Open access
ASAlana Sadur
Alana Sadur
ESEsha Sultana
Esha Sultana
ACAlejandra Curbelo-Paz
Alejandra Curbelo-Paz
MHMadison Hackley
Madison Hackley
SCSonal Choudhary
Sonal Choudhary

2 June 2026 in Dermato
Verified
Journal Article
Open access
PDF file
ACAlejandra Curbelo-Paz
Alejandra Curbelo-Paz
ELEllen Tse-Yi Lee
Ellen Tse-Yi Lee
ASAlana Sadur
Alana Sadur
NDNicholas D’Angelo
Nicholas D’Angelo
SCSonal Choudhary
Sonal Choudhary
Emerging research highlights the complex interplay between the gut microbiome, skin health, and environmental exposures, forming what is now recognized as the gut–skin–exposome axis. This narrative review explores the role of gut microbiome dysbiosis—a disruption in the balance of intestinal microorganisms—in the pathogenesis and progression of various non-communicable inflammatory skin diseases, including acne, atopic dermatitis, psoriasis, rosacea, systemic lupus erythematosus, chronic spontaneous urticaria, hidradenitis suppurativa, and alopecia areata. This review synthesizes mechanistic studies, clinical trials, and Mendelian randomization data to elucidate how altered gut microbial composition contributes to systemic and cutaneous inflammation. Key modifiable factors, such as diet, antibiotics, stress, and sleep, as well as interventions like probiotics, prebiotics, synbiotics, and fecal microbiota transplantation, are discussed for their potential therapeutic value. By integrating clinical insights with microbiome science, this review underscores the importance of a holistic, systems-based approach in managing inflammatory skin diseases, offering clinicians evidence-based strategies to improve patient outcomes through gut microbiome modulation.

9 November 2026 in Journal of Cosmetic Dermatology
Verified
Journal Article
Open access
RPReethi Padmanabhan
Reethi Padmanabhan
CGConnor Gill
Connor Gill
LJLucie Joerg
Lucie Joerg
MMMiriam Motlak
Miriam Motlak
GGGerardo Guilarte
Gerardo Guilarte
SCSonal Choudhary
Sonal Choudhary
Background: Topical peptides have emerged as a promising cosmeceutical for indications ranging from hyperpigmentation to anti‐aging. However, their role in post‐procedural wound healing following aesthetic interventions remains underexplored. Aims: The aim of this study was to systematically evaluate the evidence supporting the use of topical peptide formulations in enhancing post‐procedural wound healing and patient recovery outcomes. Methods: A systematic review was conducted to identify clinical studies evaluating topical peptide application following aesthetic dermatologic procedures, including radiofrequency microneedling and non‐ablative laser therapies. Eligible studies assessed both cosmetic and therapeutic outcomes related to wound healing and recovery. Results: Six studies met inclusion criteria across three peptide systems and across ablative laser, nonablative laser, hybrid laser, and radiofrequency microneedling procedures. Peptide formulations following ablative procedures were associated with improvements in exudation, crusting, and epithelial confluence, whereas nonablative procedures demonstrated reduced erythema and improved patient‐reported recovery outcomes, including enhanced skin appearance and texture. Studies of hybrid fractional resurfacing and radiofrequency microneedling similarly reported improvements in selected early recovery outcomes. Conclusion: Topical peptide formulations show potential as adjunctive therapies for improving post‐procedural recovery following aesthetic dermatologic procedures. However, available evidence is limited by varying procedural modalities, small sample sizes, short follow‐up intervals, and restricted demographic diversity. Larger randomized controlled trials with broader representation across Fitzpatrick skin types are necessary to better define the clinical role of topical peptide cosmeceuticals in post‐procedural wound healing.

1 January 2026 in Dermatologic Therapy
Verified
Journal Article
Open access
PDF file
NANana-Hawwa Abdul-Rahman
Nana-Hawwa Abdul-Rahman
ALAlice D. Lee
Alice D. Lee
GGGerardo Guiltarte
Gerardo Guiltarte
SCSonal Choudhary
Sonal Choudhary
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder characterized by epidermal barrier dysfunction, immune dysregulation, and intense pruritus. Although existing treatments, including topical corticosteroids, calcineurin inhibitors, and biologic agents, are effective for many patients, concerns regarding long‐term safety, cost, and incomplete disease control have driven interest in nonimmunosuppressive and complementary therapeutic strategies. L‐histidine is an essential dietary amino acid that has emerged as a potential biologic modulator in AD due to its central role in filaggrin metabolism and natural moisturizing factor (NMF) production. This narrative review synthesizes the current mechanistic, preclinical, and clinical evidence evaluating L‐histidine as a therapeutic or adjunctive intervention in AD. L‐histidine supports epidermal hydration, pH homeostasis, and barrier integrity through its role as a precursor of filaggrin‐derived NMF components. In vitro and skin‐equivalent models demonstrate that L‐histidine enhances filaggrin processing and improves functional barrier properties. Importantly, mechanistic studies indicate that histidine supplementation does not promote pathological histamine production, alleviating concerns regarding histamine‐mediated disease exacerbation. Clinical evidence, though limited to small exploratory trials and case reports, shows reductions in disease severity and pruritus in both pediatric and adult patients receiving oral L‐histidine supplementation. However, these findings should be regarded as preliminary rather than conclusive. The magnitude of improvement reported in these small trials has been described by the authors as similar to SCORAD reductions historically reported for mid‐potency topical corticosteroids. However, this is a benchmark comparison against external historical literature, not a head‐to‐head assessment. Since no head‐to‐head trial has directly compared L‐histidine with topical corticosteroids, its efficacy should not be considered equivalent or directly comparable to that of topical corticosteroids. Oral L‐histidine has demonstrated a favorable safety and tolerability profile to date, with no serious adverse events reported. L‐histidine is a low‐cost, well‐tolerated, barrier‐targeted adjunct with potential utility in AD management. Larger, long‐term randomized controlled trials incorporating genetic stratification and combination therapy designs are warranted to better define its optimal role in clinical practice.